{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:08:39Z","timestamp":1792728519801,"version":"4.5.0"},"reference-count":35,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>A woman in her 50s was a super responder to benralizumab administered for the treatment of severe bronchial asthma (BA) with eosinophilic chronic rhinosinusitis with nasal polyp (ECRS) and eosinophilic otitis media (EOM). She exhibited the gradual exacerbation of ECRS\/EOM despite good control of BA approximately 1 year after benralizumab initiation. Therefore, the treatment was switched to dupilumab, and the condition of the paranasal sinuses and middle ear greatly improved with the best control of her asthma. The patient reported that her physical condition was the best of her life. However, she developed a pulmonary opacity on chest computed tomography after 6 months. Histological examination of the lung parenchyma and cell differentiation of the bronchoalveolar lavage fluid indicated atypical chronic eosinophilic pneumonia, and treatment was switched to mepolizumab. Similarly to the period of benralizumab treatment, exacerbation of ECRS\/EOM reduced her quality of life approximately 10 months after the administration of mepolizumab. Dupilumab was again introduced as a replacement for mepolizumab. The clinical course and consideration of the interaction between inflammatory cells led us to speculate that interleukin-13 could play a key role in the development of ECRS\/EOM with severe BA.<\/jats:p>","DOI":"10.3390\/ijms222011209","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T22:52:47Z","timestamp":1634683967000},"page":"11209","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3833-7157","authenticated-orcid":false,"given":"Hideyasu","family":"Shimizu","sequence":"first","affiliation":[{"name":"Toshiwakai Clinic, Toshiwakai, Nagoya 460-0022, Japan"},{"name":"Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-6671","authenticated-orcid":false,"given":"Masamichi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Okazaki Medical Center, Department of Diagnostic Pathology, Fujita Health University School of Medicine, Okazaki 444-0827, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3790-8691","authenticated-orcid":false,"given":"Kazuyoshi","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsushi","family":"Okazawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake 470-1192, Japan"},{"name":"Department of Respiratory Medicine, Daiyukai General Hospital, Daiyukai Health System, Ichinomiya 491-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"ref_1","unstructured":"(2021, September 07). Grobal Initiative for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/gina-reports\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: The JESREC Study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11882-008-0096-5","article-title":"Eosinophilic otitis media: A new middle ear disease entity","volume":"8","author":"Iino","year":"2008","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0385-8146(01)00124-9","article-title":"Clinical characteristics of so called eosinophilic otitis media","volume":"29","author":"Nagamine","year":"2002","journal-title":"Auris Nasus Larynx"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_6","first-page":"101336","article-title":"Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report","volume":"32","author":"Shimizu","year":"2021","journal-title":"Respir. Med. Case Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/cea.12083","article-title":"Respiratory mechanics and peripheral airway inflammation and dysfunction in asthma","volume":"43","author":"Shirai","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1016\/j.bbagen.2016.08.009","article-title":"Toll-like receptor-mediated involvement of innate immune cells in asthma disease","volume":"1861","author":"Zakeri","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/imm.12945","article-title":"Differential T-cell receptor signals for T helper cell programming","volume":"155","author":"Morel","year":"2018","journal-title":"Immunology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations (*)","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"a030338","DOI":"10.1101\/cshperspect.a030338","article-title":"T Helper Cell Differentiation, Heterogeneity, and Plasticity","volume":"10","author":"Zhu","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the Pathophysiology of Severe Asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41423-019-0210-8","article-title":"Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses","volume":"16","author":"Gurram","year":"2019","journal-title":"Cell Mol. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00281-016-0556-2","article-title":"Type 2 innate lymphoid cells: At the cross-roads in allergic asthma","volume":"38","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/eji.201142018","article-title":"Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma","volume":"42","author":"Kleinjan","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting Type 2-high and Type 2-low airway inflammation in asthma: Current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lee, T.J., Fu, C.H., Wang, C.H., Huang, C.C., Huang, C.C., Chang, P.H., Chen, Y.W., Wu, C.C., Wu, C.L., and Kuo, H.P. (2017). Impact of chronic rhinosinusitis on severe asthma patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171047"},{"key":"ref_18","first-page":"1060","article-title":"Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys","volume":"291","author":"Minthorn","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J. Allergy. Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.alit.2020.01.002","article-title":"Dupilumab: Basic aspects and applications to allergic diseases","volume":"69","author":"Matsunaga","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.201207-1292OC","article-title":"Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression","volume":"187","author":"Takabayashi","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00005792-199809000-00001","article-title":"Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d\u2019Etudes et de Recherche sur les Maladies \u201cOrphelines\u201d Pulmonaires (GERM\u201cO\u201dP)","volume":"77","author":"Marchand","year":"1998","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00005792-198805000-00002","article-title":"Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature","volume":"67","author":"Jederlinic","year":"1988","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/TCRM.S157882","article-title":"Chronic eosinophilic pneumonia: Clinical perspectives","volume":"15","author":"Crowe","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/TCRM.S207402","article-title":"A case of chronic eosinophilic pneumonia in a patient treated with dupilumab","volume":"15","author":"Menzella","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1378\/chest.108.1.123","article-title":"Increase of activated T-cells in BAL fluid of Japanese patients with bronchiolitis obliterans organizing pneumonia and chronic eosinophilic pneumonia","volume":"108","author":"Mukae","year":"1995","journal-title":"Chest"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.4049\/jimmunol.1400732","article-title":"IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation","volume":"193","author":"Fulkerson","year":"2014","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)63504-3","article-title":"Respiratory reovirus 1\/L induction of intraluminal fibrosis, a model of bronchiolitis obliterans organizing pneumonia, is dependent on T lymphocytes","volume":"163","author":"Majeski","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.alit.2021.02.002","article-title":"Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media","volume":"70","author":"Hamada","year":"2021","journal-title":"Allergol. Int."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Briegel, I., Felicio-Briegel, A., Mertsch, P., Kneidinger, N., Haubner, F., and Milger, K. (2021). Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. J. Allergy Clin. Immunol. Pract.","DOI":"10.1055\/s-0042-1747691"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bcp.2008.04.002","article-title":"IL-13 as a therapeutic target for respiratory disease","volume":"76","author":"Kasaian","year":"2008","journal-title":"Biochem. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/20\/11209\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:16:58Z","timestamp":1760167018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/20\/11209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":35,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["ijms222011209"],"URL":"https:\/\/doi.org\/10.3390\/ijms222011209","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]}}}